Company Overview of MOTUS THERAPEUTICS, INC.
MOTUS THERAPEUTICS, INC., a biopharmaceutical company, develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases. The company’s product candidate, relamorelin, is a potent, ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. Its relamorelin is derived from the natural ghrelin sequence that targets the receptor for ghrelin, which is a naturally occurring hormone that plays a critical role in GI motility, digestion, and the absorption of nutrients. MOTUS THERAPEUTICS, INC. was formerly known as Rhythm Pharmaceuticals, Inc. and changed its name to MOTUS THERAPEUTICS, INC. in September 2014...
855 Boylston Street
Boston, MA 02116
Founded in 2008
Key Executives for MOTUS THERAPEUTICS, INC.
Chief Executive Officer and Director
Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2017.
MOTUS THERAPEUTICS, INC. Key Developments
Rhythm Pharmaceuticals Inc. Announces Expansion of Phase Ii Obesity Trial
May 17 17
Rhythm Pharmaceuticals Inc. announced the expansion of its Phase II clinical trials of setmelanotide to the treatment of Bardet Biedl syndrome (BBS) obesity. Setmelanotide is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. This initial study is an open-label, Phase II clinical trial of setmelanotide for the treatment of BBS obesity. The clinical trial will evaluate the safety and efficacy of setmelanotide administered once daily by subcutaneous injection in patients with BBS obesity. Setmelanotide is a potent, first-in-class MC4R agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early-onset and severe obesity.
Rhythm Pharmaceuticals Names David Meeker as Chairman
Apr 11 17
Rhythm Pharmaceuticals has appointed David Meeker as chairman of the board. Currently, Meeker serves at Genzyme as its president and chief executive officer.
Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
Apr 4 16
Motus announced the completion of enrollment for a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Motus' ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal (GI) motility. Allergan has an exclusive option to acquire Motus Therapeutics, Inc. upon the completion of this Phase 2b study. The Phase 2b trial is designed to evaluate the effect of relamorelin on signs and symptoms of gastroparesis, GI motility, and safety in patients with diabetic gastroparesis. The randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of dosing regimens ranging from 10 to 100 mcg administered twice daily over three months. The trial enrolled 396 patients with diabetic gastroparesis at clinical sites in the U.S and Europe.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 16, 2017
October 27, 2016